Armenta MVM, Angulo PG, Waizel HS, Arellano SJ, Gallegos AU

Language: Spanish
References: 9
Page: 35-40
PDF size: 230.99 Kb.

ABSTRACT

Background: Osler-Weber-Rendu syndrome is an autosomal dominant inheritance disorder, characterized by mucocutaneous and visceral telangiectasias. In 90% of the cases, recurrent epistaxis is present, the severity varies from case to case and can affect the quality of life of patients.
Clinical case: A 75-year-old female patient, diagnosed with Osler-Weber-Rendu syndrome, was admitted to our hospital due to an anterior epistaxis with a month of evolution and no remission for packing with hemostatic material, surgical exploration nor cauterization. Angiography and embolization were performed without complications.
Conclusions: Embolization is a safe procedure that can be a treatment in patients with Osler-Weber-Rendu syndrome without remission of epistaxis.

REFERENCES

1. Alvo VAs, Alzérreca E. Telangiectasia hemorrágica hereditaria: Aspectos otorrinolaringologías. Rev OtorrinolaringolCir Cabeza Cuello 2012; 72 (3): 297-305. http://dx.doi.org/10.4067/S0718-48162012000300014

2. Robard L, Michel J, Prulière Escabasse V, Bequignon E, et al. Guidelines of the French Society of Otorhinolaryngology(SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease. EurAnn Otorhinolaryngol Head Neck Dis 2017; 134 (1): 37-41. http://dx.doi.org/10.1016/j.anorl.2016.09.010

3. Di Cosola M, Cazzolla AP, Scivetti M, Testa NF, et al. Síndrome de Rendu-Osler-Weber o telangiectasiahemorrágica hereditaria (HHT): Descripción de dos casos y revisión de la literatura. Av Odontoestomatol2005; 21 (6): 297-303.

4. Mcdonald J, Bayrak-Toydemir P, Demille D, Wooderchak-Donahue W, Whitehead K. Curaçao diagnosticcriteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG orACVRL1 (HHT1 and HHT2). Genet Med 2020; 22 (7): 1201-1205. https://doi.org/10.1038/s41436-020-0775-8

5. Kühnel T, Wirsching K, Wohlgemuth W, Chavan A, et al. Hereditary hemorrhagic telangiectasia. OtolaryngolClin N Am 2018; 51 (1): 237-254. https://doi.org/10.1016/j.otc.2017.09.017

6. Merino Martín V, Bernalte Sesé A, Milara Payá J. Uso de bevacizumab para el tratamiento de la epistaxisen telangiectasia hemorrágica hereditaria: a propósito de un caso. Farm Hosp 2017; 41 (5): 651-653. https://dx.doi.org/10.7399/fh.10867

7. Zalagh M, Errami N, Bouaity B, Hemmaoui B, et al. Épistaxis grave de la maladie de Rendu-Osler-Weber[Intractable epistaxis in Osler-Rendu- Weber syndrome]. Rev Stomatologie Chir Maxillo-faciale 2011; 112(5): 310-312. https://doi.org/10.1016/j.stomax.2011.08.016

8. Layton KF, Kallmes DF, Gray LA, Cloft HJ. Endovascular treatment of epistaxis in patients with hereditaryhemorrhagic telangiectasia. AJNR Am J Neuroradiol 2007; 28 (5): 885-8.

9. Dür C, Anschuetz L, Negoias S, Bulut OC, et al. Long- term efficacy assessment of current treatment optionsfor epistaxis in HHT. Eur Arch Otorhinolaryngol 2021; 278 (11): 4321-4328. https://doi.org/10.1007/s00405-021- 06701-z